Mounjaro weight loss success stories: what really happens when people use it

What do the clinical trials actually show?

The SURMOUNT-1 study, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide or placebo for 72 weeks. Participants on the 15mg dose lost an average of around 20–21% of their starting body weight. To put that in everyday terms: someone starting at 100kg might expect, on average, to reach around 79–80kg by the end of the trial period, alongside a reduced-calorie diet and increased activity.

Those are averages. Some participants lost more; others less. A smaller group lost very little and, per the trial's own data, a meaningful minority discontinued early, usually because of side effects. Describing only the upper end of the range as the typical outcome would be misleading, which is why the success rate picture is worth reading in full alongside any individual account.

SURMOUNT-5, a head-to-head trial published in 2025, compared tirzepatide directly with semaglutide 2.4mg (Wegovy) over 72 weeks in adults with obesity and no diabetes. Tirzepatide produced a greater average reduction, a result that has attracted considerable attention, including discussion of godzilla mounjaro and what higher-end outcomes actually represent in practice. That comparison matters if you are weighing up your options, though the right choice always comes down to individual clinical suitability rather than headline figures alone.

Why do some people see bigger results than others?

A question our prescribers hear most weeks: why did one person lose 25% of their body weight on Mounjaro while someone else, on the same dose, managed 10%? There is no single answer. Biological factors (including insulin sensitivity, gut-hormone response, genetics and metabolic rate) vary between individuals in ways that are not predictable from BMI alone.

Consistency also plays a large part. Participants in SURMOUNT-1 had structured support for diet and lifestyle changes; Mounjaro is licensed alongside a reduced-calorie diet and increased physical activity, not as a standalone fix. People who maintain those changes tend to see the sustained results that make longer-term outcomes possible.

Dose matters too. Treatment starts at 2.5mg (a level designed to help the body adjust, particularly to the gastrointestinal effects) and is titrated upward by a prescriber over several months. The larger weight reductions reported in trials reflect maintenance doses, usually 10–15mg, not the starter pen. Reaching and tolerating those higher doses requires time and clinical support along the way.

Finally, duration counts. Weight loss on tirzepatide tends to continue for many months; results at 12 weeks look very different from results at 72 weeks. Short-term accounts, however enthusiastic, capture only part of the story.

Who is likely to be prescribed Mounjaro in the UK?

Mounjaro holds a UK licence for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above when at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Holding a qualifying BMI does not, on its own, guarantee a prescription; the prescriber assesses the full picture, including current medications, medical history and whether treatment is appropriate.

NICE's technology appraisal (TA1026) recommends tirzepatide for NHS use in adults with a BMI of 35 or above and at least one weight-related comorbidity, though NHS access is being phased in gradually; you can read more about how Mounjaro is used in the UK and what the NHS rollout looks like. For people who do not meet the current NHS criteria, or who would prefer not to wait, a private prescription from a regulated online pharmacy is the alternative route, provided clinical suitability is confirmed first.

For a sense of the full range of treatment options available, the weight-loss treatment overview covers what is licensed in the UK and what each option involves.

What does coming off Mounjaro mean for the results?

This is where success stories sometimes tell an incomplete tale. Evidence from the SURMOUNT programme shows that when tirzepatide is stopped, the appetite-suppressing effects diminish and weight tends to return over time, a pattern seen across the GLP-1 and dual-agonist drug class. This is not a failure of the medicine; it reflects the biology of obesity as a long-term condition rather than a short-term episode to be resolved and finished.

NICE's guidance notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, the decision to continue should be reviewed. For people who do respond well, the question of what happens next (whether to continue, pause, or taper) is a clinical conversation. Accounts of stopping Mounjaro are worth reading alongside the trial data, because real-world experience after discontinuation shapes the full picture as much as the peak results do.

If you are considering starting treatment, understanding both the results and what sustains them is part of making an informed decision. A prescriber-led consultation is the right place to work through that. At nume (sorry) at our pharmacy, every consultation is read personally by a GPhC-registered Independent Prescriber, not automated software, and clinical review continues with every repeat order. If you would like to explore whether Mounjaro is suitable for you, start your free consultation and a prescriber will assess your situation the same day.